Nonalcoholic Steatohepatitis: Lessons from Different Diet-induced Animal Models

Abstract

The nonalcoholic fatty liver disease has been considered the hepatic manifestation of the metabolic syndrome, which is prone to progress to nonalcoholic steatohepatitis, cirrhosis and hepatocellular carcinoma. Modern lifestyle, which includes less time dedicated to exercise parallel to preference for fast foods rich in fats and simple carbohydrate, has been suggested as the cornerstone for the development of metabolic impairments linked to obesity. In this way, experimental models are useful in trying to mimic metabolic pathways and morphological alterations involved with the spectrum of nonalcoholic steatohepatitis pathophysiology. Diets rich in saturated fatty acids, trans fatty acids and fructose emerge as the most relevant dietary models to induce nonalcoholic steatohepatitis. Consideration should be given to the composition of the diet and time of administration, both of which can induce many different results. Pharmacological approach aims to alleviate insulin resistance, lipotoxicity and inflammation, which are pivotal to NASH triggering. The resulting control of the underlying metabolic impairments reduces NASH expressively. All in all, the jury is still out on the adequate management of this disease. Giving that dietary patterns exert a crucial role in NASH progression, considerations should be given to the exact mechanisms by which each nutrient underpin NASH development.

Keywords

Nonalcoholic steatohepatitis; Fructose; Saturated fatty acids; Trans fatty acids; Sucrose; Treatment; Insulin resistance; Inflammation

Abbreviations

ACC: Acetyl-CoA Carboxylase; ACL: ATP-Citrate Lyase; ACOX1: Acyl CoA Oxidase; ALIOS: American Lifestyle Induced Obesity Syndrome; ALT: Alanine Transaminase; ARB: Angiotensin Receptor Blocker; AT1R: Angiotensin II Type 1 Receptor; ChREBP: Carbohydrate Responsive Element Binding Protein; CPT1a: Carnitine Palmitoyl Transferase 1a; DM2: Type 2 Diabetes Mellitus; DNL: De Novo Lipogenesis; ER: Endoplasmic Reticulum; FAS: Fatty Acid Synthase; FFAs: Free Fatty Acids; GLUT 2: Glucose Transporter 2; HFCS: High Fructose Corn Syrup; HGF: Hepatocyte Growth Factor; HHS: High Fat-High Sucrose Diet; HSCs: Hepatic Stellate Cells; ICAM-1: Intercellular Adhesion Molecules; IKKβ: IkB Kinase β; IRS-1: Insulin Receptor; MAPK: Mitogen Activated Protein Kinases; MCD: Methionine and Choline-deficient Diet; MUFA: Mono Unsaturated Fatty Acid; NAFLD: Non Alcoholic Fatty Liver Disease; NASH: Non Alcoholic Steato Hepatitis; PPAR: Peroxisome Proliferator Activated Receptor; PUFAs: Poly Unsaturated Fatty Acid; RAS: Renin Angiotensin System; SCD1: Stearoyl Coenzyme A Desaturase-1; SFA: Saturated Fatty Acid; SREBP-1: Sterol Regulatory Element Binding Proteins 1c; TGF-β: Transforming Growth Factor-beta1; TNF-α: Tumoral Necrosis Factor alpha; TRANS: Trans Fatty Acids; UCP-2: Un Coupling Protein 2; WAT: White Adipose Tissue; α-SMA: alpha Smooth Muscle Action

Introduction

Currently, NAFLD (nonalcoholic fatty liver disease) is considered the hepatic manifestation of the metabolic syndrome and may progress to NASH (nonalcoholic steatohepatitis), cirrhosis and hepatocellular carcinoma [1]. Although NAFLD and NASH are associated together, the pathogenesis of NASH is not yet completely elucidated. The pathogenesis of NASH was considered as the "first hit", characterized by the accumulation of intrahepatic lipid due to disrupting metabolic pathways and increase vulnerability to cell damage. Lipotoxicity triggers the "second hit", which encompasses increased oxidative stress that triggers the secretion of tumoral necrosis factor alpha (TNF-α) and interleukin-6 (IL-6), activation of hepatostellate cells (HSCs) and expression of cellular adhesion molecules (ICAM-1, intercellular adhesion molecules; E-selection or P-selection) [2,3]. The lipotoxicity, mitochondrial dysfunction and magnitude of oxidative stress result in lipid peroxidation, which leads to death of hepatocytes, inflammation and ultimately, fibrosis [4].

Changes in lifestyle as dietary interventions or prescriptions of exercise, as well as the pharmacological treatments have not been established. As a rule, the progression NAFLD-NASH is related to the continuity of the stimulus that generates the injury, i.e. chronic dietary fat intake [5]. These observations highlight a need to exactly understand how different nutrients underpin hepatic alterations that can result into NASH and to establish suitable approaches to tackle this metabolic constraint.

Dietary Models of NASH

Dietary models of NASH are relevant as an attempt to mimic the pathogenesis of the current epidemics of diet-induced obesity and the resulting metabolic disturbances, which includes NAFLD and NASH [1].
In general, animals fed diets rich in lipogenic nutrients, particularly simple sugars such as fructose or sucrose [6,7] and/or saturated fats [7-10], develop steatosis rather than steatohepatitis. In older animals, some evidence of hepatocellular injury, focal lobular inflammation and even early pericellular fibrosis may be observed, particularly during prolonged intake of a lipogenic diet [7,8,11]. Other commonly used fatty liver disease models are animals lacking genes that affect appetite regulation, or which predispose to diabetes [12-16].

High-fat diet and NASH

High-fat feeding when used as a model for NASH produces variable results with respect to the levels of steatosis, inflammation and fibrosis that is dependent on the rodent species, fat content, duration of treatment and qualitative composition of dietary fat [17].

Nowadays, the “two-hit” hypothesis is widely accepted as the pathogenesis of NAFLD/NASH, however, an obligatory role for oxidative stress in the progression to NASH could not been shown [18].

As an alternative hypothesis, emerging evidence now points to metabolites of fatty acids as the real culprits in the hepatocellular injury in NASH, as they are identified in other target organs of lipotoxicity. Lipotoxicity is the phenomenon that refers to the cellular dysfunction seen when accumulation of excessive lipid occurs in non-adipose tissue such as the liver [19].

The literature has shown that both quantity and quality of dietary fat influence liver fatty acid synthesis [20], insulin sensitivity and can induce IR (insulin resistance) [21]. Among high dietary fat models, intragastric overfeeding of mice seems to resemble the histopathology and pathophysiology of human NASH most closely. This model, however, requires technical expertise and specialized equipment that may hamper its widespread use.

More recent studies prefer to use overfeeding because livers of the overfed mice were metabolically characterized by an increased expression of (pericentrally located) lipogenic livers of the overfed mice were metabolically characterized by widespread use.

In an attempt to create an experimental model to study NASH, it was used a liquid high fat diet given ad libitum to Sprague-Dawley rats or a controlled daily fat intake by force-feeding Sprague-Dawley rats [24]. In these two cases, high fat diet induced mild steatosis and huge hepatic inflammation. The main fat component of these two diets was corn oil, consisting of 13% (w/w) saturated fatty acid (SFA), 24% monounsaturated fatty acid (MUFA) and 59% polyunsaturated fatty acid (PUFA). These PUFA were almost entirely composed by pro-inflammatory n-6 polyunsaturated fatty acids which are known to be involved in liver oxidative stress [25]. This rat model is suitable for diet-induced obesity.

The intragastric overfeeding of C57BL/6 mice with a high-fat diet (37% of corn oil in the diet, corresponding to 185% normal energy intake) over 9 weeks to induce NASH in male C57BL/6 mice provoked overweight (71% higher body weight), with increased visceral fat (white adipose tissue [WAT]), hyperglycemia, hyper insulinemia, hyper leptinemia, glucose intolerance and IR. Almost half of the animals (46%) developed NASH with a 5- to 6-fold increase in plasma alanine transaminase (ALT). However, these models represent excessive overfeeding and some of the biochemical changes observed in the liver did not mimic those seen in NASH patients [22]. Furthermore, the human NASH features usually have a diet with higher levels of SFA and cholesterol and low levels of PUFA [26]. It is noteworthy that C57BL/6 is an inbred mouse model that provides suitable background for studying NASH as whenever fed onto high fat diet, they manifest early metabolic syndrome features [27].

The effects of giving a high-fat diet to rodents can be highly variable. Some of this variability could be explained by the influence of rodent strain, which is known to be important in the susceptibility to several types of liver disease. In a longitudinal study, chronic administration of a high-fat diet (60% of calories from fat) led to the development of steatohepatitis in male C57BL/6 mice, after 50 weeks [28,29]. Likewise, a high-fat diet (60% lard) has been used to trigger the ”second hit” and to initiate steatohepatitis in fa/”fa” (defective long-form Leptin receptor) rats [30]. In this model, oxidative stress was proposed to initiate steatohepatitis, because there was an increase in NADPH oxidase activity, lipid peroxidation and protein carbonyl formation together with decreases in GSH and antioxidant enzymes, such as catalase. Similarly, a high-fat diet administered to foz/foz mice with a dysfunctional Alstrom syndrome 1 (ALMS1) gene induced steatohepatitis in these obese animals [31].

A murine model incorporating prolonged administration of a “western diet” with high saturated fat and cholesterol content was able to reproduce NASH with some increase in fibrosis markers, but not ballooning [32].

It’s well described the proatherogenic effect of the trans fatty acids. However, little is known about the influence of trans fatty acids on hepatic lipid metabolism. A recent study evaluated the consumption of 3 different high-fat diets (PUFA, SFA and trans Fatty acids (TRANS)) in male LDLr-KO mice (LDL Receptor Knock-Out mice) and demonstrated that the mice fed the TRANS diet had greater hepatomegaly due to fat accumulation and inflammatory NASH-like lesions and impaired glucose tolerance when compared with mice fed the PUFA and SFA diets, [33]. In agreement with another study, the TRANS diet intake elicited increased transcription of genes involved in liver fat synthesis such as PPAR-γ and Sterol regulatory element-binding
Proteins 1c (SREBP-1c) and was associated with higher hepatic cholesterol and TG concentrations compared with the PUFA and SFA diets [34]. Recently, LDLr-KO mice have been described as a suitable model to detect the onset inflammation in NAFLD, which is crucial to NASH development [35].

Another study observed that NASH was induced by the American lifestyle induced obesity syndrome (ALIOS diet) model for an initial period of 16 weeks. The ALIOS model includes feeding male C57BL/6 mice with high fat, trans-fat enriched chow and consumption of high fructose corn syrup resulting in a NASH-like liver histological phenotype [36].

Fructose and NASH

The consumption of sugar incorporate in the diet increased their rates by 3 times in the last 50 years in a global context [37]. The corn syrup, high fructose (HFCS) is a sweetener produced by the isomerization of existing glucose fructose corn syrup. HFC-90 (90% 9% fructose and glucose) is the main product of such chemical reactions and is diluted with glucose syrup to form HFCS - and HFCS 42 - 55, these are the most commonly used in processed foods and beverages as soft drinks, fruit and bread to yogurts [38]. The low cost and easy handling pointed to the main attractions for increased consumption [39,40].

In 1986, the average intake of fructose has increased 16% from 56g/day to 65g/day in 2007 [41]. The 74g/day consumption, equivalent to 2.5 cans of soda affect a rise in blood pressure without cardiovascular risk [42].

Along with the increasing growth of the amount of fructose in the diet, an increase in the presence of obesity, IR and hypertension in the United States, leading producer of high-fructose syrup from corn [37]. Studies report that more than 10% of daily calories come from fructose. Ingestion of a sweetening agent in the diet is 75% in adults and 82% children [43].

Glucose transporter 2 (GLUT2) mediates the entry of fructose in the liver and fructokinase rapidly phosphorylates it into fructose-1P. Fructose-1P is converted into dihydroxyacetone and glyceraldehyde-3P. The latter will have different targets:

a) Participate into the glycolytic pathway providing pyruvate and releasing energy in the Krebs cycle

b) A part of the P-trioses produced can be converted to lactate (25%) and being released into the blood vessels

c) Be reduced to glycerol, necessary to form lipids, triglycerides and phospholipids – it means that a part of the carbon atoms of fructose can be converted to FFAs within hepatocytes by the process of DNL (de novo lipogenesis)

d) Form fructose 1,6-diphosphate and thereafter forming glucose (50%) and glycogen (>15%) by gluconeogenesis, which is the major portion. Fructose-1P still activates protein kinase (7-8), which in turn activate Mitogen-activated protein kinases (MAPK) family proteins (MAPK7 and MAPK8) that induces serine phosphorylation of the insulin receptor (IRS-1) leading to hepatic IR [44].

In hepatic lipogenesis, lipid oxidation is inhibited by fructose, favoring the formation of fatty acids linked to glycerol, triglycerides and VLDL. Despite being the smallest amount of fructose converted into fatty acid, chronic intake pre-offers the framework of hepatic steatosis. Increased DNL associated with the process of dyslipidemia and hepatic steatosis, mechanisms promoted by fructose [44]. The continuous production of acetyl-CoA due to mobilization of fructose exceeds the responsiveness of mitochondria (Krebs cycle) and this excess is converted to citrate, leaving the cytosol and being the substrate for DNL. In addition, acetyl-CoA form malonyl-CoA (reaction mediated ACC - acetyl-CoA carboxylase) inhibits the action of CPT-1a, decreasing the input of fatty acids into the mitochondria for oxidation [45]. On the other hand, fructose directly or indirectly activates transcription factors (SREBP-1c and Carbohydrate responsive element-binding protein - ChREBP) responsible for the activation of genes encoding enzymes of DNL (ACL, ATP-citrate lyase; ACC and FAS), leading to production of VLDL and triglycerides. All factors combined culminate with the storage of fat in the form of macro and micro vesicles within hepatocytes [44].

For the analysis of NAFLD and NASH, it is not conclusive to say that the effects of chronic ingestion of fructose develop these valences. Various parameters such as dose-response, time and delivery vehicle are offered from many experimental studies [46].

The onset of hepatic steatosis frames for possible progression to NASH, mediated by obesity; these lipogenic effects are not dependent on the increase of body mass [47]. Sprague Dawley rats fed a 60% fructose for 28 days showed increased levels of mRNA factors transition of hepatic lipogenesis (ACC, FAS, SREBP-1c and ChREBP) without change in body mass. On the other hand, Wistar rats fed with 70% fructose for 5 weeks showed large amount of macro and micro vesicles of fat and intra hepatic intralobular inflammation [8]. C57BL/6 mice consuming a diet rich in fat and carbohydrate intake associated with the 55% fructose in water for 16 weeks developed significant fibrosis with NASH and obesity [7]. We observe livers from C57BL/6 mice subjected to 34% fructose or fructose combined with a high-fat diet (34% fructose and 42% lipid - lard) for 16 weeks, showing inflammatory infiltrate [depicted in (Figure 1a and 1b)] [48]. The results show that mice fed a high-fructose diet are good models for the development of NASH [49,50].

Sucrose and NASH

Studies in animals have found that high carbohydrate diet induced histopathological features of the NAFLD and NASH, especially when administered at high doses [6,5,5-53]. Some studies have shown the induction of NAFLD and NASH by high-sucrose diet, alone or in interaction with other diets. In this model, hepatic steatosis occurs first and steatohepatitis develops later. On the other hand, in a dietary model induced by methionine and choline deficiency, steatohepatitis occurs very quickly [54-57]. Discrepancy between studies may be partially a result of differences in the experimental diet and its time administration period.

The metabolic pathways accomplishing carbohydrate
conversion into fat are well known and they were well characterized in earlier studies [58,59]. In animal models, numerous studies have addressed the effects of diets enriched with fructose or sucrose. Several studies using animal models have shown that a high-sucrose diet leads to hepatic steatosis. Wistar rats fed a high-sucrose diet showed an induction of multiple components of the unfolded protein response in the liver consistent with endoplasmic reticulum (ER) stress, and hepatic lipid accumulation, liver injury and inflammation [60]. In other study, male C57BL/6 mice fed a high-carbohydrate diet (65% sucrose) for long-term (16 weeks) induced typical hepatic steatosis and, for the feeding period employed, the liver did not display markers of hepatitis (inflammation, necrosis and others) [6]. Whether feeding this diet for longer periods may lead to NASH remains to be established.

Current evidence shows that sucrose diet altered the liver structure. C57BL/6 mice fed to 32% sucrose for 8 weeks showing abundant micro- and macrovesicular steatosis with areas of inflammatory infiltrate [61] (Figure 2).

Interestingly, adult male Sprague-Dawley rats fed with high-sucrose diet (70% sucrose) for 2 or 3 weeks developed fatty livers and became obese, being the fat distributed periportally and the absolute weights of the livers and liver/body weight ratio increased by 20% [7], while as Wistar rats fed with a sucrose rich diet (70% sucrose) for 5 weeks demonstrated mild steatosis, inflammation and lipogranulomas in the liver tissues, without steatohepatitis [8]. Moreover, C57BL/6 mice fed a 65% sucrose diet for 8 weeks exhibit obesity, IR and macrovesicular steatosis [62].

Experimental studies seldom identify potential genes/pathways that may contribute to the progression of liver steatosis to NASH. Enzymes involved into glucose and fructose metabolism and their conversion to fat [59,63] were up regulated by the high-sucrose diet model. In addition, the transcription factor SREBP-1c, which controls the transcription of genes involved in fatty acid synthesis [64], and whose transcription is regulated by insulin [65], were up regulated.

The metabolism of sucrose-rich diets generates fructose, which exerts acute effects on hepatocyte energy homeostasis [11]. Thus, pathology that occurs during the chronic ingestion of high-sucrose diets is caused by fructose. The phosphorylation of fructose causes an abrupt decline in hepatocyte ATP content that gradually recovers as phosphofructose and is metabolized via the pentose phosphate shunt. The activity of this metabolic pathway requires a sufficient pool of diet that causes purine depletion and exacerbates the fatty liver that is caused by high-fructose diets in rats [11,66].

Mixed models

Diets that are enriched with a high-sucrose/fructose diet develop steatosis in Fischer 344 rats [67]. In addition, Zucker fatty (fa/fa) rats are also particularly sensitive to fatty livers induced by feeding 60% sucrose or orotic acid (1%) [68]. In all strains of rodents that have been evaluated, males are more susceptible to fatty liver than females.

Emerging data indicate that specific dietary nutrients, as sucrose, when coupled with methionine and choline deprivation, can influence MCD-mediated liver disease [52]. Recent study reported a diet model of NASH by using a MCD diet associated a sucrose diet, in which C3H/HeJ mice developed hepatic steatosis, hepatocellular apoptosis, alanine aminotransferase elevation, lipid peroxidation and hepatic inflammation [52]. Others studies have shown that mice feeding of high-sucrose (54%) diets that are also deficient in choline (0.05%) for 6 months showed perivenous fatty change and hepatic fibrosis in most of the rats.
had the greatest NASH rate of all rats groups, but C57Bl/6 mice (Dawley) and C57Bl/6 mice. It was found that male Wistar strain diet using male and female rats (Wistar, Long-Evans and Sprague-Dawley) and C57Bl/6 mice. It was found that male Wistar strain fed MCD-diet may depends on the species, gender and strain of the animal [75]. A study [76] has compared the effects of MCD-diet in the liver, however without histopathological features of NASH [70].

Methionine- and choline-deficient-diet

The methionine- and choline-deficient-diet (MCD) is frequently utilized to establish NASH in the rodent liver. Rodents fed MCD-diet develop steatohepatitis producing changes on the redox balance and hepatic lesions that mimic the impairment of patients with NASH [72,73]. It happens because the choline and the methionine amino acids are essentials for hepatic β-oxidation and production of VLDL [50]. Choline is an essential nutrient that participates in cell membrane integrity, phosphatidylycholine synthesis, transmembrane signaling, neurotransmission and methyl metabolism. Dietary with choline deficiency promotes hepatic steatosis and reduces plasma VLDL level as well established in the literature. It was thought that these effects were caused due to impaired synthesis of phosphatidylcholine, which could diminish VLDL synthesis and secretion, but observations [74] have brought doubts about it and suggest other mechanisms and further studies to define the role of choline deficiency in steatosis [54]. Furthermore, the lack of the methionine, an essential nutrient as well as choline, increases oxidative stress, impairs phosphatidylethanolamine synthesis and the transport of fat from the liver to extrahepatic sites causing hepatic steatosis [72]. It fits highlight that mice fed a diet that is deficient in both choline and methionine develop inflammation and hepatic fibrosis in addition to steatosis [54].

Serum alanine aminotransferase level is consistently increased after MCD-diet administration, steatohepatitis in this diet-model occurs at day 10, and perisinusoidal fibrosis is observed by 8-10 weeks in mice. After 10 weeks of MCD-diet administration, it can be observed extensive macrovesicular steatosis in all areas except in the periportal region and many necroinflammatory foci containing lymphocytes, and neutrophils are observed in mice [50]. Nevertheless, it is important to note that although the MCD-diet causes these effects, NASH in rodents fed MCD-diet may depends on the species, gender and strain of the animal [75]. A study [76] has compared the effects of MCD-diet using male and female rats (Wistar, Long-Evans and Sprague-Dawley) and C57Bl/6 mice. It was found that male Wistar strain had the greatest NASH rate of all rats groups, but C57Bl/6 mice developed the most expressive necrosis and inflammation, in addition to the best histological features of NASH.

Evidences suggest that MCD-diet leads to induction of alcohol-inducible CYP2E1 expression that also is observed on patients with NASH. These findings support the hypothesis that alcoholic and nonalcoholic steatohepatitis could share the same pathogenic mechanisms [77,78]. CYP2E1 is a member of the cytochrome P450 mixed-function oxidase system and can produce ROS by mitochondria. These ROS, in turn, cause peroxidation of membrane lipids resulting in alteration of the membrane function. Moreover, products of peroxidation of lipids can react with functional groups of amino acids of proteins and enzymes, altering their function, as in uncoupling protein-2 (UCP-2) and CPT-1 [73,79].

By decreasing oxidative defense mechanisms, MCD-diet creates a situation that is known to induce TNF-alpha and others proinflammatory cytokines. Oxidants and TNF-alpha are also expected to activate the IκB kinase β (IκKB) pathway that interacts with others pathway signaling as insulin and renin angiotensin system (RAS). However and interestingly, this NASH model did not develop the metabolic profile observed in typical patients with NASH. Animals fed the MCD-diet are cachectic and show significant weight loss (often, more than 20% weight loss after three weeks and 50% compared with control mice by 10 weeks), low fasting glucose, serum insulin, Leptin and triglycerides levels and peripheral insulin sensitivity. An unchanged or an increased Adiponectin level in plasma is also observed [80-82]. Moreover, the histological distribution of hepatic steatosis differs from the pattern seen in humans where a periportal rather than perivenous deposition is noted [66].

Taking all these information into account, we can highlight two main conclusions: first, MCD-diet is an excellent model to induce steatohepatitis in mice models rather than in rats models, even some changes in Wistar rat being observed; and second, MCD-diet reproduces the inflammatory and lipid profiles of NASH, including activation of RAS and HSCs, but differently of human NASH, this diet did not reproduce the metabolic profile, induces a significant weight loss and present some difference between loc of collagen deposition in liver. To improve the metabolic problems, it is frequent use some genetically obese mice, such as ob/ob and db/db mice. Finally, the main advantage of the MCD-diet is that it is easy to obtain and use [50].

Pharmacological Treatment

Drug treatment to NASH should target metabolic alterations that underpin NAFLD and inflammation [83,84]. Insulin sensitizers have become the main approach, given that IR is closely linked to hepatic steatosis development [85]. More recently, an important role in the pathogenesis of NAFLD was attributed to angiotensin II and the use of angiotensin receptor blockers (ARBs) to tackle NASH has been put forward. Hypolipidemic agents such as fibrates and statins have also been addressed owing to the prevailing involvement of lipoprotein metabolism disturbances into hepatic lipotoxicity [86].
Insulin sensitizers

**Metformin:** Metformin has been the first option to treat type 2 diabetes mellitus (DM2) since 1994 when it was approved by Food and drug administration. It is a biguanide, causing reduction of hepatic glucose production, which in turn, alleviates hepatic IR. In humans, Metformin seems to be efficient in reducing hepatic steatosis parallel to decreased inflammation and fibrosis [85,87].

Concerning experimental data, administration of 0.1% of Metformin during 8 weeks provoked substantial reduction of hepatic triglyceride, reversed hepatic steatosis in histological evaluation, suppressed HSCs activation, reduced the transcription of genes involved with lipogenesis, inflammation and fibrogenesis in mice fed MCD+HFD [88].

**Thiazolidinediones:** PPAR-γ agonist, such as Pioglitazone, is widely used to counter IR and promote diabetes control [89]. PPAR-gamma is a transcription factor that regulates gene expression in many tissues, mainly in liver and white adipose tissue, being crucial to hepatic lipogenesis and adipogenesis, respectively. Besides, therapy with PPAR-gamma agonist has been linked with inhibition of cell proliferation and collagen expression in HSCs in vitro and in vivo [90,91], making PPAR-gamma agonists a potential approach to treat NASH.

Pioglitazone (1mg/Kg day) prevented rats with NASH due to MCD diet from developing cirrhosis. A significant amelioration of liver histology, followed by decreased expression of alpha smooth muscle actin (α-SMA), transforming growth factor-beta1 (TGF-β), procollagen and TNF-α was observed [92]. All of these endpoints highlight efficiency in tackling inflammation and fibrosis prevention.

Higher levels of circulating adiponectin, which enhances insulin sensitivity and ameliorates NASH, have been reported in rodents under Rosiglitazone treatment [93,94]. In Sprague-Dawley rats with NASH induced by high-fat high-cholesterol diet, treatment with 4 mg/Kg day of Rosiglitazone yielded modulation of adiponectin receptor in liver (decrease) and white adipose tissue (increase). Reduced circulating levels of TNF-α also contributed to tackle NASH as it is inversely correlated with adiponectin levels [95,96].

**Other agents:** Glucagon like peptide-1 analog also exhibits positive effects, minimizing body mass, liver mass, liver steatosis and fibrosis in ob/ob mice with NASH induced by high trans-fat diet [97]. Sitagliptin (dipeptidyl peptidase-4 inhibitor) reduced steatosis, ameliorated hepatic ultra structure by enhancing beta-oxidation and reducing lipogenesis in the liver of C57BL/6 mice fed with a high saturated-fat diet, preventing from NASH development [98].

**Angiotensin Receptor Blockers (ARB)**

RAS activation is involved in liver fibrosis due to activation of HSCs, which mainly express angiotensin II type 1 receptor (AT1R). By blockade of AT1R, Telmisartan inhibits HSCs activation by angiotensin II, reducing liver fibrosis [111,162]. Furthermore, Telmisartan acts as partial PPAR-γ agonist and, hence, has been indicated as the first-class option for patients with NASH [86].

In the MCD diet model, Telmisartan markedly alleviated hepatic steatosis, inflammation, and fibrosis in Fischer rats when compared to Valsartan (pure ARB). Conversely, Pioglitazone (total PPAR-gamma agonist) reduced NAFLD, but did not decrease subcutaneous and visceral fat like Telmisartan did [99]. Then, dual ARB/PPAR-gamma agonist appears as the most promising approach to tackle NASH.

Due to selective PPAR-gamma activation, Telmisartan ameliorates IR and promotes ectopic fat redistribution into proliferating adipocytes, reducing glucolipotoxicity [100,101]. In C57BL/6 mice fed MCDHF diet, the treatment with telmisartan (10 mg/Kg day) had striking effects upon liver steatosis, hepatic triglycerids and fibrogenesis. Treated animals showed rise in adiponectinemia, reduced size of adipocytes, suppression of macrophage infiltration into liver, decreased expression of mRNA for type 1 collagen and TGFβ1, implying inhibition of fibrogenesis and prevention of hepatocellular carcinoma [100].

Likewise, a study pursued in rats fed chronically with MCD diet showed that the daily dose of 3 mg/kg of Telmisartan has the potential to improve NASH possibly owing to increased hepatocyte growth factor (HGF) production. This observation emphasizes the partial PPAR-gamma agonist property of Telmisartan, making this drug differs and be more attractive than others ARBs [102]. Even with diagnosis of cirrhosis after 24 weeks feeding rats with MCD diet, Telmisartan at the dose of 2 mg/Kg day avoided hepatocellular carcinoma occurrence [103]. After all, Telmisartan has been reported as a suitable strategy to prevent NAFLD from becoming NASH in different diet-induced models [98,102].

**Fibrates**

PPAR-alpha is essential to the β-oxidation process within hepatocytes, which counteracts lipogenesis making output of FFAs surpasses their input, alleviating hepatic steatosis. For that reason, Fenofibrate (pure PPAR-alpha agonist) has been used to treat NASH [104,105]. In APOE2 knock-in mice fed with a western diet, Fenofibrate treatment decreased hepatic macrophage accumulation, which preceded hepatic steatosis and abolished hepatic lipotoxicity. This observation was accounted for by massive reduction in the expression of inflammatory genes and increased expression in β-oxidation related genes, all of which were PPAR-alpha target genes. In addition, procollagen type 1 expression was diminished by fibrate [106,107].

Bezafibrate (50 or 100mg/Kg day), a pan-PPAR agonist, and GWS501516 (10mg/Kg day), a PPAR-delta agonist, inhibited the MCD-diet-induced NASH. Both of them increased the levels of hepatic mRNAs linked to beta-oxidation and lipid transportation within hepatocytes concomitant with reduction in the levels of mRNA associated with inflammatory cytokines. Bezafibrate also enhanced levels of adiponectin and its receptors 1 and 2, ameliorating IR, which has a pivotal role in liver lipotoxicity [80].

**Other drug classes**

Nifedipine, a calcium channel blocker, activates PPAR-gamma. Hence, it targets IR and inflammation, two paramount features
in NASH pathogenesis. In a rat model of NASH due to MCD diet, Nifedipine effects bore resemblance to Bezafibrate treatment, emerging as a promising option to treat NASH in hypertensive individuals [108].

Statins are the most prescribed drug to treat dyslipidemia worldwide. Nearly 70% of patients with NASH have dyslipidemia, which justify its evaluation in NASH. Rosuvastatin has striking effects upon diet induced NAFLD in C57BL/6, favoring β-oxidation instead of lipogenesis and blocking inflammatory pathways [109]. In humans, preliminary studies indicate favorable effects of treatment with Atrovastatin and Rosuvastatin in patients with NASH [110,111]. However, results seem to be inconclusive, for instance, simvastatin did not show positive effects upon NASH [112]. Works that are more detailed should be carried out to unravel the benefits and safety of using statins to control NASH.

Overall, taking into account the largely controversial clinical data and the vast amount of options to treat NASH indicated by experimental studies, attention should be drawn to high cost and known side effects of pharmacological agents while choosing. (Figure 3) summarizes the main effects of the drugs proposed to treat NASH.

Conclusion

Taken together, the animal studies described above clearly configure excellent models to induce steatohepatitis, mainly in mice and rats. These experimental models are useful in trying to mimic metabolic pathways and morphological alterations involved with the spectrum of NASH pathophysiology in humans. Diets rich in nutrients like SFA, Trans fatty acids, fructose, sucrose or even the absent of others (like methionine and choline) may disrupt different pathways, yielding nonalcoholic steatohepatitis. Consideration should also be given to the time of administration, which can induce many different results. Since NAFLD is considered the hepatic manifestation of MS and may progress to NASH, it is essential to understand the molecular mechanisms involved in the development of this disease. In this way, pharmacological approach aims to alleviate IR, lipotoxicity and inflammation, which are pivotal to NASH triggering. All efforts in trying to treat or avoid NASH are relevant, given that it represents greater risk to Hepatocellular carcinoma and cirrhosis, both of which exhibit higher lethality and can be induced by dietary inadequacies facing the recent nutritional transition and global obesity pandemic.

References

1. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, et al. (2001) Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50(8): 1844-1850.
2. Jaeschke H (2011) Reactive oxygen and mechanisms of inflammatory liver injury: present concepts. J Gastroenterol Hepatol 26(Suppl 1): 173-179.
3. Lee KS, Buck M, Hoeglum K, Chojkier M (1995) Activation of hepatic stellate cells by TGF alpha and collagen type I is mediated by oxidative stress through c-myb expression. J Clin Invest 96(5): 2461-2468.
4. Day CP (2002) Pathogenesis of steatohepatitis. Best Pract Res Clin Gastroenterol 16(5): 663-678.
5. Cave M, Deaciu I, Mendez C, Song Z, Joshi-Barve S, et al. (2007) Nonalcoholic fatty liver disease: predisposing factors and the role of nutrition. J Nutr Biochem 18(3): 184-195.
6. Deaciu IC, Song Z, Peng X, Barve SS, Song M, et al. (2008) Genomewide transcriptome expression in the liver of a mouse model of high carbohydrate diet-induced liver steatosis and its significance for the disease. Hepatol Int 2(1): 39-49.
7. Kohr R, Kirby M, Xanthakos SA, Sofite S, Feldstein AE, et al. (2010) High-fructose, medium chain trans fat diet induces liver fibrosis and elevates plasma coenzyme Q9 in a novel murine model of obesity and nonalcoholic steatohepatitis. Hepatology 52(3): 939-944.
8. Kawasaki T, Igarashi K, Koeda T, Sugimoto K, Nakagawa K, et al. (2009) Rats fed fructose-enriched diets have characteristics of nonalcoholic hepatic steatosis. J Nutr 139(11): 2067-2071.
9. Lieber CS, Leo MA, Mak KM, Xu Y, Cao Q, et al. (2004) Model of nonalcoholic steatohepatitis. Am J Clin Nutr 79(3): 502-509.
10. Winzell MS, Ahren B (2004) The high-fat diet-fed mouse: a model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes. Diabetes 53(Suppl 3): S215-S219.
11. Poulsom R (1986) Morphological changes of organs after sucrose or fructose feeding. Prog Biochem Pharmacol 21: 104-134.
12. Campbell LA, Smith FJ, Burn P (1996) The OB protein (leptin) pathway—a link between adipose tissue mass and central neural networks. Horm Metab Res 28(12): 619-632.
13. Kersten S, Seydoux J, Peters JM, Gonzalez FJ, Desvergne B, et al. (1999) Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. J Clin Invest 103(1): 1499-1508.
14. Moitra J, Mason MM, Olive M, Krylov D, Gavrilova O, et al. (1998) Life without white fat: a transgenic mouse. Genes Dev 12(20): 3168-3181.
15. Phillips MS, Liu Q, Hammond HA, Dugan V, Hey PJ, et al. (1996) Leptin receptor missense mutation in the fatty Zucker rat. Nat Genet 13(1): 18-19.
16. Shimomura I, Hammer RE, Richardson JA, Ikemoto S, Bashmakov Y, et al. (1998) Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: model for congenital generalized lipodystrophy. Genes Dev 12(20): 3182-3194.
Nonalcoholic Steatohepatitis: Lessons from Different Diet-induced Animal Models

17. London RM, George J (2007) Pathogenesis of NASH: animal models. Clin Liver Dis 11(1): 55-74.

18. Syn WK, Yang L, Chiang DJ, Qian Y, Jung Y, et al. (2009) Genetic differences in oxidative stress and inflammatory responses to diet-induced obesity do not alter liver fibrosis in mice. Liver Int 29(8): 1262-1272.

19. Unger RH (2003) The physiology of cellular lipro regulation. Annu Rev Physiol 65: 333-347.

20. Buettner R, Parhofer KG, Woenckhaus M, Wrede CE, Kunz-Schughart LA, et al. (2006) Defining high-fat-diet rat models: metabolic and molecular effects of different fat types. J Mol Endocrinol 36(3): 485-501.

21. Manco M, Cahanani M, Mingrone G (2004) Effects of dietary fatty acids on insulin sensitivity and secretion. Diabetes Obes Metab 6(6): 402-413.

22. Deng QG, She H, Cheng JH, French SW, Koop DR, et al. (2005) Steatohepatitis induced by intragastric feeding in mice. Hepatology 42(4): 905-914.

23. Baumgardner JN, Shankar K, Hennings L, Badger TM, Ronis MJ (2008) A new model for nonalcoholic steatohepatitis in the rat utilizing total enteral nutrition to overfeed a high-polyunsaturated fat diet. Am J Physiol Gastrointest Liver Physiol 294(1): 627-638.

24. Zou Y, Li J, Lu C, Wang J, Ge J, et al. (2006) High-fat emulsion-induced rat model of nonalcoholic steatohepatitis. Life Sci 79(11): 1100-1107.

25. Vos JS, Ning SM, Pantuck CR, Pantuck EJ, Yang CS (1991) Regulation of hepatic microsomal cytochrome P450IIIE1 level by dietary lipids and carbohydrates in rats. J Nutr 121(7): 959-965.

26. Musso G, Gambino R, De Michieli F, Cassader M, Zizzuto M, et al. (2003) Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology 37(4): 909-916.

27. Black BL, Croom J, Eisen EJ, Petro AE, Edwards CL, et al. (1998) Differential effects of fat and sucrose on body composition in A/J and C57BL/6 mice. Metabolism 47(11): 1354-1359.

28. Larter CZ, Yeh MM (2008) Animal models of NASH: getting both pathobiology and metabolic context right. J Gastroenterol Hepatol 23(11): 1635-1648.

29. Ito M, Suzuki J, Tsujikawa S, Sasaki M, Morimura A, et al. (2007) Longitudinal analysis of murine steatohepatitis model induced by chronic exposure to high-fat diet. Hepatol Res 37(1): 50-57.

30. Carmiel-Haggai M, Cederbaum AI, Nieto N (2005) A high-fat diet leads to the progression of non-alcoholic fatty liver disease in obese rats. FASEB J 19(1): 136-138.

31. Arsov T, Larter C, Nolan CJ, Petrovsky N, Goodnow CC, et al. (2006) Adaptive failure to high-fat diet characterizes steatohepatitis in Alms1 mutant mice. Biochem Biophys Res Commun 342(4): 1152-1159.

32. DeLeve LD, Wang X, Kanel GC, Atkinson RD, McCuskey RS (2008) Prevention of hepatic fibrosis in a murine model of metabolic syndrome with nonalcoholic steatohepatitis. Am J Pathol 173(4): 993-1001.

33. Machado RM, Stefano JT, Oliveira CP, Mello ES, Ferreira FD, et al. (2010) Intake of trans fatty acids causes nonalcoholic steatohepatitis and reduces adipose tissue fat content. J Nutr 140(6): 1127-1132.

34. Cassagnon N, Palos-Pinto A, Costet P, Breilh D, Darmon M, et al. (2005) Low amounts of trans 18:1 fatty acids elevate plasma triacylglycerols but not cholesterol and alter the cellular defence to oxidative stress in mice. Br J Nutr 94(3): 345-352.

35. Biggs V, Van Gorp PJ, Wouters T, Hendriks T, Gijsbers MJ, et al. (2012) LDL receptor knock-out mice are a physiological model particularly vulnerable to study the onset of inflammation in non-alcoholic fatty liver disease. PLoS One 7(1): e30668.

36. Tetri LH, Basaranoglu M, Brun特 EM, Yerian LM, Neuschwander-Tetri BA (2008) Severe NAFLD with hepatic necroinflammation. Plasmonic in mice fed trans fats and a high-fructose corn syrup equivalent. Am J Physiol Gastrointest Liver Physiol 295(5): G987-G995.

37. Lustig RH, Schmidt LA, Brindis CD (2012) Public health: The toxic truth about sugar. Nature 482(7383): 27-29.

38. Parker K, Salas M, Nwosu VO (2010) High fructose corn syrup: Production, uses and public health concerns. Biotechnology and Molecular Biology Review 5(5): 71-78.

39. Hanover LM, White JS (1993) Manufacturing, composition, and applications of fructose. Am J Clin Nutr 58(Suppl): 724S-732S.

40. Moeller SM, Fryhofer SA, Osbahr AJ, Robinowitz CB, Council on Science and Public Health, et al. (2009) The effects of high fructose syrup. J Am Coll Nutr 28(6): 619-626.

41. Tappy L, Le KA (2010) Metabolic effects of fructose and the worldwide increase in obesity. Physiol Rev 90(1): 234-46.

42. Jalal DI, Smits G, Johnson RJ, Chonchol M (2010) Increased fructose associates with elevated blood pressure. J Am Soc Nephrol 21(9): 1543-1549.

43. Vos MB, Kimmons JE, Gillespie C, Welsh J, Blanck HM (2008) Dietary fructose consumption among US children and adults: the Third National Health and Nutrition Examination Survey. Medscape J Med 10(7): 160.

44. Lim JS, Mietus-Snyder M, Valente A, Schwarz JM, Lustig RH (2010) The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome. Nat Rev Gastroenterol Hepatol 7(5): 251-264.

45. McGarry JD (1995) Malonyl-CoA and carnitine palmitoyltransferase I: an expanding partnership. Biochem Soc Trans 23(3): 481-485.

46. Wiensperger N, Geloen A, Rapin JH (2010) Fructose and cardiometabolic disorders: the controversy will, and must, continue. Clinics (Sao Paulo) 65(7): 729-738.

47. Janevski M, Ratnayake S, Siljanovski S, McGlynn MA, Cameron-Smith D, et al. (2012) Fructose containing sugars modulate mRNA of lipogenic genes ACC and FAS and protein levels of transcription factors ChREBP and SREBP1c with no effect on body weight or liver fat. Food Funct 3(2): 141-149.

48. Schultz A, Neill D, Aguila MB, Mandarim-de-Lacerda CA (2013) Hepatic adverse effects of fructose consumption independent of overweight/obesity. Int J Mol Sci 14(11): 21873-21886.

49. Nanning AA (2004) Animal models of nonalcoholic fatty liver disease and steatohepatitis. Clin Liver Dis 8(3): 559-574.

50. Takahashi Y, Sugimura M, Fukusato T (2012) Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol 18(19): 2300-2308.

51. Pickens MK, Ogata H, Soon RK, Grenet JP, Maher J (2010) Dietary fructose exacerbates hepatic injury when incorporated into a methionine-choline-deficient diet. Liver Int 30(8): 1229-1239.

52. Pickens MK, Yan JS, Ng RK, Ogata H, Grenet JP, et al. (2009) Dietary...
Nonalcoholic Steatohepatitis: Lessons from Different Diet-induced Animal Models

Highly purified eicosapentaenoic acid prevents the progression of hepatic steatosis by repressing monounsaturated fatty acid synthesis in high-fat/high-sucrose diet-fed mice. Prostaglandins Leukot Essent Fatty Acids 80(4): 229-238.

Yang ZH, Miyahara H, Takeo J, Katayama M (2012) Diet high in fat and sucrose induces rapid onset of obesity-related metabolic syndrome partly through rapid response of genes involved in lipogenesis, insulin signalling and inflammation in mice. Diabetol Metab Syndr 4(1): 32.

Pelz S, Stock P, Brukner S, Christ B (2012) A methionine-choline-deficient diet elicits NASH in the immunodeficient mouse featuring a model for hepatic cell transplantation. Exp Cell Res 318(3): 276-287.

Serviddio G, Giudetti AM, Bellanti F, Priore P, Rollo T, et al. (2011) Oxidation of hepatic carnitinepalmitoyltransferase-I (CPT-I) impairs fatty acid beta-oxidation in rats fed a methionine-choline deficient diet. PLoS One 6(9): e24084.

Kulinski A, Vance DE, Vance JE (2004) A choline-deficient diet in mice inhibits neither the CDP-choline pathway for phosphatidylcholine synthesis in hepatocytes nor apolipoprotein B secretion. J Biol Chem 279(23): 23916-23924.

Fan JG, Qiao L (2009) Commonly used animal models of non-alcoholic steatohepatitis. Hepatobiliary Pancreat Dis Int 8(3): 233-240.

Kirsch R, Clarkson V, Shephard BG, Marais DA, Jaffer MA, et al. (2003) Rodent nutritional model of non-alcoholic steatohepatitis: species, strain and sex difference studies. J Gastroenterol Hepatol 18(11): 1272-1282.

Weltman MD, Farrell GC, Hall P, Ingelman-Sundberg M, Liddle C (1998) Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology 27(1): 128-133.

Weltman MD, Farrell GC, Liddle C (1996) Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation. Gastroenterology 111(6): 1645-1653.

Serviddio G, Bellanti F, Tamborra R, Rollo T, Capitanio N, et al. (2008) Uncoupling protein-2 (UCP2) induces mitochondrial proton leak and increases susceptibility of non-alcoholic steatohepatitis (NASH) liver to ischaemia-reperfusion injury. Gut 57(7): 957-965.

Nagasawa T, Inada Y, Nakano S, Tamura T, Takahashi T, et al. (2006) Effects of bezafibrate, PPAR pan-agonist, and GW505156, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet. Eur J Pharmacol 536(1-2): 182-191.

Binella ME, Green RM (2004) The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance. J Hepatol 40(1): 47-51.

Larter CZ, Yeh MM, Williams J, Bell-Anderson KS, Farrell GC (2009) MCD-induced steatohepatitis is associated with hepatic adipocyte resistance and adipogenic transformation of hepatocytes. J Hepatol 49(3): 407-416.

Duvnjak M, Tomasic V, Gomercic M, Smircic Duvnjak L, Barsic N, et al. (2009) Therapy of nonalcoholic fatty liver disease: current status. J Physiol Pharmacol 60(Suppl 7): 57-66.

Schattenberg JM, Schuppan D (2011) Nonalcoholic steatohepatitis: the therapeutic challenge of a global epidemic. Curr Opin Lipidol 22(6): 479-488.

Stein LL, Dong MH, Loomba R (2009) Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: Current status. Adv Ther 26(10): 893-907.

Citation: Schultz A, Carlo Magliona DA, Bringhenti I, da Silva SB, da Silva Faria T, et al. (2014) Nonalcoholic Steatohepatitis: Lessons from Different Diet-induced Animal Models. J Diabetes Metab Disord Control 1(3): 00014. DOI: 10.15406/jdmcd.2014.01.00014
Nonalcoholic Steatohepatitis: Lessons from Different Diet-induced Animal Models

86. Georgescu EF (2008) Angiotensin receptor blockers in the treatment of NASH/NAFLD: Could they be a first-class option? Adv Ther 25(11): 1141-1174.

87. Hookman P, Barkin JS (2003) Current biochemical studies of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) suggest a new therapeutic approach. Am J Gastroenterol 98(2): 495-499.

88. Kita Y, Takamura T, Mieh H, Ota T, Kurita S, et al. (2012) Metformin prevents and reverses inflammation in a non-diabetic mouse model of nonalcoholic steatohepatitis. PLoS One 7(9): e43056.

89. Olefsky JM, Saltiel AR (2000) PPAR gamma and the treatment of insulin resistance. Trends Endocrinol Metab 11(9): 362-368.

90. Miyahara T, Schrum L, Rippe R, Xiong S, Yee HF, et al. (2000) Peroxisome proliferator-activated receptors and hepatic stellate cell activation. J Biol Chem 275(46): 35715-35722.

91. Galli A, Grabb DW, Cesi E, Salzano R, Mello T, et al. (2002) Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology 122(7): 1924-1940.

92. Uto H, Nakanishi C, Ido A, Hasuake S, Kusumoto K, et al. (2005) The peroxisome proliferator-activated receptor-gamma agonist, pioglitazone, inhibits fat accumulation and fibrosis in the livers of rats fed a choline-deficient, L-amino acid-defined diet. Hepatol Res 32(4): 235-242.

93. Nakayama H, Otabe S, Yuan X, Ueno T, Hirota N, et al. (2009) Effects of adiponectin transgenic expression in liver of nonalcoholic steatohepatitis model mice. Metabolism 58(7): 901-908.

94. Philips SA, Kung JT (2010) Mechanisms of adiponectin regulation and use as a pharmacological target. Curr Opin Pharmacol 10(6): 676-683.

95. Tomita K, Oike Y, Teratani T, Taguchi T, Noguchi M, et al. (2008) Hepatic AdipoR2 signaling plays a protective role against progression of nonalcoholic steatohepatitis in mice. Hepatology 48(2): 458-473.

96. Liu S, Wu HJ, Zhang ZQ, Chen Q, Liu B, et al. (2011) The ameliorating effect of rosiglitazone on experimental nonalcoholic steatohepatitis is associated with regulating adiponectin receptor expression in rats. Eur J Pharmacol 650(1): 384-389.

97. Trenvaskis JL, Griffin PS, Wittmer C, Neuschwander-Tetri BA, Brunt EM, et al. (2012) Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice. Am J Physiol Gastrointest Liver Physiol 302(8): G762-772.

98. Souza-Mello V, Gregorio BM, Cardoso-de-Lemos FS, de Carvalho L, Aguilera LB, et al. (2010) Comparative effects of telmisartan, sitagliptin, and metformin alone or in combination on obesity, insulin resistance, and liver and pancreas remodelling in C57BL/6 mice fed on a very high-fat diet. Clin Sci (Lond) 119(6): 239-250.

99. Fujita K, Yoneda M, Wada K, Mawatari H, Takahashi H, et al. (2007) Telmisartan, an angiotensin II type 1 receptor blocker, controls progress of nonalcoholic steatohepatitis in rats. Dig Dis Sci 52(12): 3455-3464.

100. Kudo H, Yata Y, Takahara T, Kawai K, Nakayama Y, et al. (2009) Telmisartan attenuates progression of steatohepatitis in mice: role of hepatic macrophage infiltration and effects on adipose tissue. Liver Int 29(7): 988-996.

101. Kuwashiro S, Terai S, Oishi T, Fujisawa K, Matsumoto T, et al. (2011) Telmisartan improves nonalcoholic steatohepatitis in medaka (Oryziaslatipes) by reducing macrophage infiltration and fat accumulation. Cell Tissue Res 344(1): 125-134.

102. Nakagami H, Kiyomi Osako M, Nakagami F, Shimosato T, Minobe N, et al. (2010) Prevention and regression of non-alcoholic steatohepatitis (NASH) in a rat model by metabosartan, telmisartan. Int J Mol Med 26(4): 477-481.

103. Tamaki Y, Nakade Y, Yamauchi T, Makino Y, Yokohama S, et al. (2013) Angiotensin II type 1 receptor antagonist prevents hepatic carcinoma in rats with nonalcoholic steatohepatitis. J Gastroenterol 48(4): 491-503.

104. Zambon A, Cusi K (2007) The role of fenofibrate in clinical practice. Diab Vasc Dis Res 4(Suppl 3): S15-20.

105. Ban S, Kasuga J, Nakagome I, Nobusada H, Takayama F, et al. (2011) Structure-based design, synthesis, and nonalcoholic steatohepatitis (NASH)-preventive effect of phenylpropanoic acid peroxisome proliferator-activated receptor (PPAR) alpha-selective agonists. Bioorg Med Chem 19(10): 3183-3191.

106. Laloyer F, Wouters K, Baron M, Caron S, Vallee E, et al. (2011) Peroxisome proliferator-activated receptor-alpha gene level differentially affects lipid metabolism and inflammation in apolipoprotein E2 knock-in mice. Arterioscler Thromb Vasc Biol 31(7): 1573-1579.

107. Shiri-Sverdlov R, Wouters K, van Gorp PJ, Gijbels MJ, Noel B, et al. (2006) Early diet-induced non-alcoholic steatohepatitis in ApoE2 knock-in mice and its prevention by fibrates. J Hepatol 44(4): 732-741.

108. Nakagami H, Shimamura M, Miyake T, Shimosato T, Minobe N, et al. (2012) Nefidipine prevents hepatic fibrosis in a non-alcoholic steatohepatitis model induced by an L-methionine- and choline-deficient diet. Mol Med Rep 5(1): 37-40.

109. Fraulob JC, Souza-Mello V, Aguila MB, Mandarim-de-Lacerda CA (2012) Beneficial effects of rosuvastatin on insulin resistance, adiposity, inflammatory markers and non-alcoholic fatty liver disease in mice fed on a high-fat diet. Clin Sci (Lond) 123(4): 259-270.

110. Hyogo H, Tazuma S, Arhiro K, Iwamoto K, Nabeshima Y, et al. (2008) Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia. Metabolism 57(12): 1711-1718.

111. Nakahara T, Hyogo H, Kimura Y, Ishitobi T, Arhiro K, et al. (2012) Efficacy of rosuvastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: An open-label pilot study. Hepatol Res 42(11): 1065-1072.

112. Nelson A, Torres DM, Morgan AE, Fincke C, Harrison SA (2009) A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: A randomized placebo-controlled trial. J Clin Gastroenterol 43(10): 990-994.

Citation: Schultz A, Carlo Maglino DA, Brighenti I, da Silva SB, da Silva Faria T, et al. (2014) Nonalcoholic Steatohepatitis: Lessons from Different Diet-induced Animal Models. J Diabetes Metab Disord Control 1(3): 00014. DOI: 10.15406/jdmdc.2014.01.00014